Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 24, 2021, titled "Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGTexclusivity".